William McCulloch

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

Sean Whittaker, Marie‐France Demierre, Ellen J. Kim et al. · Journal of Clinical Oncology · 2010 · 661 citations

Medicine, Oncology, Pharmacology +13

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau et al. · EClinicalMedicine · 2021 · 275 citations · Full text

Medicine, Oncology, Pharmacology +14

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

Rohit Loomba, Rizwana Mohseni, Kathryn Jean Lucas et al. · Gastroenterology · 2021 · 217 citations · Full text

Medicine, Internal Medicine, Pharmacology +11

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

L. Rhoda Molife, Gerhardt Attard, Peter C.C. Fong et al. · Annals of Oncology · 2009 · 184 citations

Medicine, Oncology, Pharmacology +17

A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer

Walter M. Stadler, Kim Margolin, Sandy Ferber et al. · Clinical Genitourinary Cancer · 2006 · 153 citations

Medicine, Oncology, Pharmacology +11